Kornimate/medical-research-clean huggingface dataset:
rapid antigen testing for sars-cov-2 among healthcare workers to prevent spread of covid-19

Conditions: SARS-CoV-2 Rapid Antigen Test

Summary: physicians, nurses and hospital attendants currently working at the university clinic of respiratory and allergic diseases golnik were invited to participate in the pilot study. nasopharyngeal swabs were obtained three times per week for two consecutive weeks and tested with a point-of-care rapid antigen test and reverse transcription polymerase chain reaction (rt-pcr). in addition, serum samples were obtained at the beginning of the study and 2 weeks after last swab was obtained in order to evaluate the serological status of participating health care workers.

health care workers (hcw) currently working at the university clinic of respiratory and allergic diseases golnik were invited to enroll in the pilot study. hcw directly involved in covid-19 patient care and those who had a previous laboratory confirmed sars-cov-2 infection were not eligible for inclusion in the study. for each participating hcw, nasopharyngeal swabs were obtained. swabs were collected on mondays, wednesdays and fridays for two consecutive weeks with a maximum of six samplings per person scheduled. swabs were inserted into universal transport medium (utm) and tested with sars-cov-2 rapid antigen test (roche diagnostics gmbh, mannheim, germany), in accordance with the manufacturer's instructions. briefly, samples were thoroughly vortexed and 350 μl of utm were mixed with the extraction buffer included in the testing kit. three drops of the mixture were applied to the specimen well of the lateral flow test device and results were visually read after a 15 min incubation at room temperature. nasopharyngeal swab samples were subsequently tested for the presence of sars-cov-2 rna without intermitting freeze-thaw cycle. viral rna was isolated from the specimens using the qiaamp viral rna mini kit (qiagen gmbh, hilden, germany). pcr amplification was set up on cfx96 touch real-time pcr detection system (bio-rad laboratories - dubai branch, dubai, united arab emirates) and a commercially available pcr kit allplex™2019-ncov (seegene, seoul, south korea) was used. allplex™2019-ncov assay enables simultaneous detection and identification of three target genes, specific for sars-cov-2 (e.g. the e, rdrp, and n gene). samples were considered positive for sars-cov-2 only if all three targeted genes were amplified. in addition, serum samples were collected at the beginning of the study and 14 days after the last nasopharyngeal swab was obtained. the presence of antibodies against sars-cov-2 were evaluated using idk anti-sars-cov-2 igm and igg elisa kit (immundiagnostik ag, bensheim, germany), following manufacturer's instructions.

Eligibility criteria:
inclusion criteria: * health care worker exclusion criteria: * previous known covid 19 infection
fasting-mimicking diet and immunosenescence

Conditions: Immunosenescence

Summary: the objective of this study is to test a fasting-mimicking diet (fmd) for its efficacy on improving immune response to flu vaccination in an older adult population (50-75 years of age).

this is a randomized clinical trial to test the safety and efficacy of the fasting-mimicking diet (fmd) in an elderly population (50-75 years of age) receiving their annual influenza vaccination. the study will include two arms: control (normal diet) and fmd (2 cycles of 5-day fasting-mimicking diet within two months). participants both arms will receive the standard influenza vaccine.the primary endpoint is anti-influenza antibody titers measured 4 weeks after flu vaccination. secondary endpoints include: (1) body composition changes, measured as bmi, waist to hip ratio; (2) physiological changes, measured as blood chemistry and motor performance; (3) health outcomes, measured by sf-36 health survey, dry eye surveys and flu incidents within 12 months of vaccination.

Eligibility criteria:
inclusion criteria: * ability and willingness to provide written informed consent; * ability and willingness to undergo 2 cycles of a 5-day dietary regimen; * ability and willingness to provide blood samples via venipuncture; * seeking to get a seasonal influenza vaccine. exclusion criteria: concomitant medications * received flu (influenza) shot for the flu season; * receiving immunosuppressive therapy (i.e., oral prednisone in doses \> 10 mg daily); * on immunosuppressive drugs for cancer or rheumatologic therapy; * receiving insulin or octreotide; * on hypertension medication. the subject must obtain the treating doctor's approval prior to beginning the study. safety-based exclusions: * hemoglobin \< 9.0 g/dl; * white blood cell count \< 3,500/mm\^3; * neutrophil count \< 2,000/mm\^3, * platelet count \< 125,000/mm\^3; * medical conditions that are incompatible with the dietary intervention ; * medical conditions that are incompatible with the flu vaccination; * pregnant or nursing female; * alcohol dependency;

Keywords: dietary intervention fasting-mimicking influenza vaccines
a multicenter randomized controlled study of photoelectric detection in cervical cancer screening

Conditions: Uterine Cervical Cancer; Cervical Intraepithelial Neoplasia; High Grade Squamous Intraepithelial Lesions; Low Grade Squamous Intraepithelial Lesions

Summary: the main purpose of this study is to verify the accuracy of the fluorescence photoelectric cervical lesion image detector relative to the pathological gold standard and the detection rate of cin 2 +, as well as the significance of it as a shunt tool before colposcopy through a randomized controlled study. the secondary objectives were to compare the relative pathological accuracy of the fluorescence photoelectric cervical lesion image detection results with the hpv detection results and cytological results, and to compare the lesion area displayed by the fluorescence photoelectric cervical lesion image detector with the lesion area that appeared after traditional colposcopy chemical staining. in this study, 4200 subjects who have been evaluated and can be enrolled (these subjects have the indication of referral to colposcopy) will be included in the study, and they will be divided into two groups according to the principle of randomization. the histological results were obtained after routine colposcopy and biopsy. the experimental group first underwent colposcopy and biopsy after the judgment of the fluorescent photoelectric cervical lesion image detector to obtain histological results. finally, the accuracy of the relative pathological results, the detection rate of cin2 +, negative predictive value and positive predictive value of the two groups were compared.


Eligibility criteria:
inclusion criteria: * 1. age ≥ 18 years old, ≤ 65 years old, with a complete cervix without deformity. * 2. have clear cervical cancer screening results, meet hpv16/18 (+) or high-risk hpv (+), and cervical cytology results ≥ asc-us. * 3. fully informed and agreed to participate in the study. * 4. no history of cervical cancer disease and cancer in other parts. exclusion criteria: * 1. cannot meet all inclusion criteria. * 2. there is clear immunosuppression, such as hiv infection or organ transplantation, etc., and the vagina or cervix is in the acute inflammation stage。 * 3. there are serious bleeding diseases or photosensitive diseases such as abnormal coagulation.
ultrasonication-mediated microbubbles dressing for hand arthritis

Conditions: Hand Arthritis

Summary: the goal of this clinical trial is to learn if ultrasonication-mediated microbubbles dressing works to treat hand arthritis in adults. it will also learn about the safety of ultrasonication-mediated microbubbles dressing. the main questions it aims to answer are: does ultrasonication-mediated microbubbles dressing increase the therapeutic efficacy of piroxicam gel for hand arthritis? researchers will compare "ultrasonication-mediated microbubbles dressing + piroxicam gel " to "ultrasonication + piroxicam gel" and "piroxicam gel alone" to see if ultrasonication-mediated microbubbles dressing works to treat hand arthritis. participants will: take "ultrasonication-mediated microbubbles dressing (day 1,3,5) + piroxicam gel (day 2,4,6,7) ", "ultrasonication (day 1,3,5) + piroxicam gel (day 2.4.6.7)", and "piroxicam gel alone (day 1-7)" for 1 week. visit the clinic on day 1 and day 8 for checkups and tests keep a diary of their symptoms


Eligibility criteria:
inclusion criteria: * clinical diagnosis of hand arthritis * have at least three symptomatic joints over wrist, metacarpophalangeal joints, and interphalangeal joints exclusion criteria: * infectious arthritis * acute gout
neurofeedback in individuals with substance use disorders

Conditions: Opioid-Related Disorders

Summary: the aim of this study is to train individuals with opioid use disorder to control their brain activity in a way that has been associated with their symptoms. participants in the experimental group will be given direct feedback regarding their brain activity while they are undergoing functional magnetic resonance imaging (fmri) scanning, and will try to learn to control their brain activity during these feedback sessions. a separate group of participants will be given a control form of feedback that we do not believe can have clinical benefits. our primary hypothesis is that the neurofeedback training will reduce opioid use and clinical features of opioid use disorder more than the control feedback.


Eligibility criteria:
inclusion criteria: 1. non-methadone opioid positive urine screen (as assessed during standard treatment) or indicated via utox or self-reported past-month opioid use at screening 2. diagnostic and statistical manual of mental disorders (dsm)-5 criteria for opioid use disorder, as assessed via structured clinical interview (scid) 3. ≥3 months of methadone treatment exclusion criteria: 1. having any current neurologic or psychiatric disorders including current moderate to severe other dsm-5 substance use disorders with the exceptions of opioids, cocaine, tobacco and cannabis, as assessed using the scid. 2. failure to pass a magnetic resonance imaging (mri) screening 3. having significant underlying medical conditions requiring medications. 4. women who are pregnant or nursing 5. baseline scanning with excessive motion based on frame to frame displacement
blood components changes by using of ringer's lactated as detergent in autologous blood cell transfusion

Conditions: Placenta Accreta Spectrum

Summary: placenta accreta spectrum (pas) disorders are associated with increased maternal morbidity and mortality related to life-threatening hemorrhage, and greater potential need for blood transfusion. clinical evidences have confirmed that the use of autologous blood cell transfusion is safe and effective for patients with obstetric haemorrhage. normal saline is the solution recommended for red cell washing, administration and salvage. however, there is growing concern that normal saline is more toxic than balanced, buffered crystalloids such as lactated ringer's and plasma-lyte. the purpose of this study is to evaluate the blood components using of ringer's lactated by a prospective, single-center, open, and single-arm clinical trial.


Eligibility criteria:
inclusion criteria: * between 18 and 45 years old * without health problem nor disease requiring regular medical treatment exclusion criteria: * subject with contraindication for drawing blood * subject with physical or mental disability or restriction of liberty that would prevent autotransfusion

Keywords: placenta accreta spectrum autologous blood cell transfusion blood components
a cultural adaptation of the caregiver tlc psychoeducational program to support latino caregivers (cuidando juntos)

Conditions: Caregivers of People With Dementia

Summary: this study will test the feasibility and influence of a behavioral intervention called "cuidando juntos" in latino caregivers of people with dementia. the study will examine if the intervention is well received by latino caregivers and if the caregivers' social connectedness and loneliness is associated with their levels of stress, burden, and depression.


Eligibility criteria:
inclusion criteria: * spanish speaking * latino caregivers are those who identify as the primary caregivers of a person with dementia, with whom they co-reside or live close by. * must have an email address and access to the internet * caregivers should report at least a moderate level of stress exclusion criteria: * none
restorative eye treatment and inhance in upper eyelid blepharoplasty surgery

Conditions: Eyelid Dermatochalasis; Dermatochalasis

Summary: the purpose of this research is to determine if restorative eye treatment (ret) and inhance with trihex technology used before and after blepharoplasty can lead to better skin quality before undergoing blepharoplasty, and if these products will lead to less visible scarring and faster healing after blepharoplasty.


Eligibility criteria:
inclusion criteria: 1. men and women who are about to have blepharoplasty at the bascom palmer eye institute by dr. wendy lee. 2. men and women with no known medical conditions that, in the investigator's opinion, may affect wound healing and interfere with study participation (e.g. diabetes, skin disorder etc.). 3. participants willing to provide consent for photographic release. 4. participants must not be using any new skincare products, other than the study products provided, on the treatment area for the duration of the study. 5. participants willing to avoid extended periods of sun exposure and all use of tanning beds for the duration of the study. 6. participants must be willing to refrain from any other treatments or procedures to the treatment area during the duration of the study. 7. 18 years old or older. exclusion criteria: 1. any dermatological disorder or poor health, which in the investigator's opinion, may interfere with the accurate evaluation of the participants' skin characteristics or inhibit wound healing. 2. participants who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study products. 3. participants that have been using topical products around their upper or lower eyes within 30 days. 4. participants who are, in the opinion of the investigator, unwilling or unable to comply with the requirements of the protocol. 5. pregnant or lactating participants will be excluded, as well as participants planning on becoming pregnant during the study duration. 6. participants with recent excessive exposure to sunlight or artificial uv light (e.g.: use of tanning beds/booths and/or sunbathing). 7. a participant with a history of keloids or hypertrophic scars. 8. participants known to harbour a blood borne disease (e.g. hepatitis a virus (hav), hepatitis b virus (hbv), hepatitis c virus (hcv ), hiv) 9. special populations: prisoners, pregnant women, adults unable to consent, individuals who are not yet adults. 10. have any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements.

Keywords: blepharoplasty
research of quality of life and safety outcomes of postmenopausal breast cancer patients switching from tamoxifen therapy to aromatase inhibitor therapy

Conditions: Breast Neoplasms

Summary: the purpose of this study is to follow safety and quality of life outcomes on patients switching from tamoxifen therapy to aromatase inhibitor therapy.

group of patients using the same aromatase inhibitor

Eligibility criteria:
inclusion criteria: patients with endocrine responsive early stage postmenopausal breast cancer. patients who received tamoxifen for 2-3 years as adjuvant endocrine therapy. patients who were approved to switch to aromatase inhibitor treatment during the patient recruitment period. patients who were informed about the study and accepted to participate. exclusion criteria: patients having a psychological disorder which will prevent their understanding of questionnaires used for evaluation of quality of life and / or patients who are illiterate.

Keywords: aromatase inhibitor quality of life safety postmenopausal breast cancer
arterial inflammation and e-cigarettes

Conditions: Arterial Inflammation

Summary: arterial inflammation will be compared using pet scanning in 3 groups: 1) non-smokers, 2) tobacco cigarette smokers, 3) electronic cigarette users.

qualified participants will undergo a singe pet/ct to detect arterial inflammation.

Eligibility criteria:
inclusion criteria: healthy * nonsmokers or * daily e-cigarette user or * daily tobacco cigarette smoker exclusion criteria: * cardiac disease * respiratory disease * diabetes mellitus

Keywords: arterial inflammation electronic cigarettes pet scan
trial of thiamine supplementation in cambodia

Conditions: Thiamine Deficiency

Summary: beriberi is a potentially fatal disease caused by vitamin b1 (thiamine) deficiency that still occurs in southeast asia despite near eradication elsewhere. mothers with a diet low in thiamine produce thiamine-poor milk, putting their infants at a high risk of developing thiamine deficiency and beriberi. there is also a growing body of evidence suggesting thiamine deficiency not severe enough to cause clinical symptoms may negatively effect cognitive development and functioning of the infant. since human milk should be the sole source of nutrition for babies during the first six months, maternal thiamine intake must be improved to combat this disease. the investigators' recent study of thiamine-fortified fish sauce in cambodia showed that fortification could increase maternal and infant thiamine status'. however, centrally produced fish sauce may not reach the poorest communities who make their own fish sauce, and fish sauce is not consumed in all regions where we find thiamine deficiency. salt, by contrast, is a common condiment in most regions of the world and has proven to be a successful global fortification vehicle for iodine. suboptimal maternal thiamine intake puts exclusively breastfed infants at risk of low thiamine status, impaired cognitive development, and infantile beriberi, which can be fatal. thiamine fortification of salt is a potentially low-cost and sustainable means of combating suboptimal thiamine status; however knowledge gaps must be filled before thiamine fortification can proceed. in this study, mothers will consume thiamine supplements in order to model the thiamine dose required to optimize human milk thiamine concentrations for the prevention of beriberi. other thiamine biomarkers will be assessed, and usual salt intake will be measured. finally, the investigators will assess the effects of early-life thiamine exposure on infant neuro-cognitive development.

(see full protocol)

Eligibility criteria:
inclusion criteria: mothers of a newborn who: * are aged 18 - 45 years * had a recent normal pregnancy (i.e. no known chronic conditions, no preeclampsia, gestational diabetes etc), and the singleton infant was born without complications (e.g. low birth weight (\<2.5 kg), tongue tie, cleft palate) * are intending to exclusively breastfeed for six months * reside in kampong thom province, cambodia, and are not planning to move in the next six months * are willing to consume one capsule daily from 2 weeks through to 24 weeks postpartum * are willing for her entire household consume only salt provided by the study team * are willing for the following biological samples to be collected: a maternal venous blood sample and human milk sample at 2 weeks postpartum, a human milk sample at 4 and 12 weeks postpartum, and maternal and infant blood samples and a human milk sample at 24 weeks postpartum. exclusion criteria: mothers of a newborn who: * are currently taking or has taken thiamine-containing supplements over the past 4 months * are currently participating in nutrition programs beyond normal care
a weight maintenance program promoting fat loss in pregnancy in women with obesity

Conditions: Gestational Weight Gain; Obesity

Summary: the aims of this randomized controlled trial are to determine the effects of a lifestyle program that supports weight maintenance and fat mass loss during pregnancy in women with obesity on changes in 1) maternal weight, fat mass, and cardiometabolic risk factors; 2) safety measures, including fetal and neonatal growth; 3) the mediators and moderators of the fat mass loss intervention and 4) the effects gestational fat mass loss has on reducing incidence of adverse obstetrical outcomes, including non-elective cesarean delivery, gestational diabetes, hypertension, and pre-eclampsia.

one hundred pregnant women with obesity who are otherwise healthy will be studied from early pregnancy until approximately 2 weeks postpartum. major assessments will occur at baseline (13-16 weeks gestation), 27-29 weeks gestation, 35-37 weeks gestation, and approximately 2 weeks postpartum. safety assessments will be collected every 4 weeks after enrollment. participants will be randomized within site (approximately 50 individuals at pennington biomedical research center and approximately 50 individuals at california polytechnic university) and obesity to either: provider directed group or weight maintenance group.

Eligibility criteria:
inclusion criteria: * are pregnant less than or equal to 15 weeks gestation at screening * have a body mass index between 31.0 and 55.0 inclusive * have a confirmed viable singleton gestation * willing to receive randomization to either group * willing and able to eat the study foods * willing to enroll infant for study measurements after birth * receive clearance from the prenatal care provider for participation exclusion criteria: * smoking, drug, or alcohol use * have a known fetal anomaly * have a non-pregnancy related illness * have pre-existing diabetes * have pre-existing hypertension * have severe anemia * have current mental health issue or eating disorder * short inter-pregnancy interval (\<6 months since last pregnancy) * use of assisted reproductive technology * use of medications with known effects on body weight including over the counter medications and supplements for weight loss * history of pre-eclampsia, prior small for gestational age infant, bariatric surgery * planning to move out of the area in the next 12 months

Keywords: pregnancy body composition
cross-cultural adaptation and validation of the pelvic girdle questionnaire in french language

Conditions: Pelvic Girdle Pain; Pregnancy Related; Postpartum Period

Summary: the objective of this study is the adaptation of the pelvic girdle questionnaire to the french language from france, and the analysis of its psychometric properties. firstly, a translation and adaptation process will be performed according to international guidelines. secondly, the validation process will be performed through a sample of 250 pregnant or postpartum women suffering from pelvic girdle pain. they will fill several questionnaires, including pelvic girdle questionnaire, that will allow us to analyse psychometric properties of the french version.


Eligibility criteria:
inclusion criteria: * women from 18 years-old, pregnant or having given birth less than one year earlier, with pgp whose onset occurred during pregnancy or within 3 weeks after birth. registered in the french social security system. exclusion criteria: * ovarian cysts, uterine fibroids, caesarean section (if subject in postpartum period), radicular pain below the knee, previous surgery on the spine, pelvis or lower limbs, vaginismus-type pelvic pain, spondylolisthesis, inflammatory diseases, prolapse, suspected serious pathology (weakness of the lower limbs, reflex changes or loss of sensation associated with the same spinal nerve), impossibility or difficulty in understanding the questionnaires and subjects needing guardianship/supervision.